| Title |
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 2012
|
| DOI | 10.2147/dmso.s21979 |
| Pubmed ID | |
| Authors |
Fei Wang, Justine Surh, Manmeet Kaur |
| Abstract |
Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 33% |
| India | 1 | 33% |
| Spain | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | 1% |
| India | 1 | 1% |
| Unknown | 71 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 18% |
| Student > Ph. D. Student | 12 | 16% |
| Researcher | 8 | 11% |
| Student > Postgraduate | 8 | 11% |
| Student > Doctoral Student | 5 | 7% |
| Other | 18 | 25% |
| Unknown | 9 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 41% |
| Biochemistry, Genetics and Molecular Biology | 8 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Agricultural and Biological Sciences | 4 | 5% |
| Chemistry | 3 | 4% |
| Other | 10 | 14% |
| Unknown | 12 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2022.
All research outputs
#2,078,708
of 25,728,855 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#102
of 1,190 outputs
Outputs of similar age
#12,270
of 177,377 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#2
of 10 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,190 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.